High plasma prolactin is associated with PRL-R and predicts poor prognosis in Chinese postmenopausal women with breast cancer
Indian Journal of Cancer · 2025
DOI: 10.4103/ijc.ijc_1018_21 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Cancer, 2025. Verfasst von Lifang He und 8 weiteren Autor:innen. Beteiligte Einrichtung: Breast Center, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China. Hauptthemen laut MEDLINE: Prolactin, Receptors, Prolactin, Breast Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Background
Prolactin (PRL) plays an important role in mammary epithelial cell development and lactation. Increased levels of PRL are observed in human breast cancer, but the underlying mechanism and prognostic significance of PRL are still controversial. In this study, we sought to determine the significance of PRL in Chinese postmenopausal women with breast cancer.
Methods
Plasma PRL levels in 326 healthy individuals and 333 postmenopausal breast cancer patients were analyzed. Immunohistochemical staining of cytoplasmic prolactin receptor (PRL-R) was performed. Moreover, the relationships between plasma PRL and clinicopathological parameters as well as survival in breast cancer patients were evaluated.
Results
We found that high plasma levels of PRL was more common in breast cancer patients than in healthy individuals. We also observed that high level of PRL was associated with adverse prognostic factors, such as larger tumor size, more lymph node metastasis, advanced tumor stage, negative estrogen receptor (ER) expression, and negative progesterone receptor (PR) expression of breast cancer. Kaplan–Meier analysis showed that high plasma level of PRL correlated with poor disease-free and overall survival, while Cox regression models demonstrated that high plasma level of PRL was an independent prognostic marker for disease-free survival. The rate of PRL-R positivity among those with high plasma PRL was significantly higher than that of patients with low PRL ( P < 0.05).
Conclusion
The plasma PRL level and PRL-R expression in tumor tissue may be prognostic for Chinese postmenopausal women with breast cancer. The inhibition of PRL and PRL-R signaling is a potential therapeutic approach for endocrine therapy in breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Breast Center, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.
- Guangdong Provincial Key Laboratory for Breast Cancer Diagnosis & Treatment, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.
- Breast Center, People's Hospital of Jieyang, Jieyang, Guangdong, China.
- Department of Pathology, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.
- Breast Center, People's Hospital of Chaozhou, Chaozhou 521000, Guangdong, China.
- Department of Breast and Thyroid Surgery, Shunde Hospital of Southern Medical University, Foshan, Guangdong, China.
Zitieren
APA
He, L., Jin, X., Wu, J., Wei, X., Huang, G., Hong, Y., Li, Y., Liang, P., & Huang, W. H. (2025). High plasma prolactin is associated with PRL-R and predicts poor prognosis in Chinese postmenopausal women with breast cancer. Indian Journal of Cancer. https://doi.org/10.4103/ijc.ijc_1018_21
Vancouver
He L, Jin X, Wu J, Wei X, Huang G, Hong Y, et al. High plasma prolactin is associated with PRL-R and predicts poor prognosis in Chinese postmenopausal women with breast cancer. Indian Journal of Cancer. 2025. doi:10.4103/ijc.ijc_1018_21
BibTeX
@article{He2025,
author = {He, Lifang and Jin, Xiaolong and Wu, Jundong and Wei, Xiaolong and Huang, Guangsheng and Hong, Yingsong and Li, Yaoquan and Liang, Peide and Huang, Wen-He},
title = {High plasma prolactin is associated with PRL-R and predicts poor prognosis in Chinese postmenopausal women with breast cancer},
journal = {Indian Journal of Cancer},
year = {2025},
doi = {10.4103/ijc.ijc_1018_21}
}
EUVIMED